Department of Zoology, Panjab University, Chandigarh, 160014, India.
Med Microbiol Immunol. 2015 Aug;204(4):539-50. doi: 10.1007/s00430-014-0367-9. Epub 2014 Nov 29.
Visceral leishmaniasis (VL) caused by Leishmania donovani is a life-threatening disease involving uncontrolled parasitization of vital organs. Drugs to treat leishmaniasis have one or more limitations or insufficiencies in the long run. A safe and efficacious vaccine to control this disease is needed. Killed antigens that could be safer as vaccines have shown limited efficacy in clinical trials. Immunogenic enhancement with appropriate adjuvants may thus be required to elicit protective immunity based on antibodies and effector T-cell functions. Therefore, it is essential to search for adjuvant to enhance the immunogenicity of killed vaccines and to induce protection against leishmaniasis. So, the aim of the present study was to compare the effectiveness of four adjuvants, i.e. alum, saponin, monophosphoryl lipid A, cationic liposome in combination with Killed Leishmania donovani (KLD) antigen against murine VL. Animals were immunized subcutaneously thrice at an interval of 2 weeks with a final volume of 100 μl per dose. Challenge infection was given 2 weeks after last booster. Mice were sacrificed 15 days after last immunization and on 30, 60 and 90 post-infection/challenge days. The protective efficacy of vaccines was revealed by significant reduction in parasite burden and enhanced DTH responses in comparison with the infected controls. Immunized animals also generated significant levels of Th1 cytokines and increased production of IgG2a, thus indicating the generation of a protective Th1 response. All the adjuvants imparted significant protection, but liposomal formulation was most effective followed by KLD + MPL-A, KLD + saponin, KLD + alum and KLD antigen.
内脏利什曼病(VL)由杜氏利什曼原虫引起,是一种危及生命的疾病,涉及重要器官的失控寄生虫化。长期以来,治疗利什曼病的药物都存在一种或多种局限性或不足。需要一种安全有效的疫苗来控制这种疾病。作为疫苗的已杀死抗原的安全性更高,但在临床试验中显示出有限的疗效。因此,可能需要使用适当的佐剂来增强免疫原性,以基于抗体和效应 T 细胞功能来诱导保护性免疫。因此,寻找佐剂来增强已杀死疫苗的免疫原性并诱导针对利什曼病的保护是至关重要的。因此,本研究的目的是比较 4 种佐剂,即明矾、皂素、单磷酰脂质 A、阳离子脂质体与已杀死杜氏利什曼原虫(KLD)抗原联合使用对小鼠内脏利什曼病的有效性。动物通过皮下免疫三次,每次间隔 2 周,每次剂量为 100 μl。最后一次加强免疫后 2 周进行攻击感染。最后一次免疫后 15 天处死小鼠,并在感染/攻击后 30、60 和 90 天。与感染对照组相比,疫苗的保护效力通过寄生虫负荷的显著减少和 DTH 反应的增强来揭示。免疫动物还产生了显著水平的 Th1 细胞因子,并增加了 IgG2a 的产生,这表明产生了保护性 Th1 反应。所有佐剂都赋予了显著的保护作用,但脂质体制剂最有效,其次是 KLD+MPL-A、KLD+皂素、KLD+明矾和 KLD 抗原。